The Benefits of Add-on Therapy of Vitamin D 5000 IU to the Vitamin D Levels and Symptoms in Diabetic Neuropathy Patients: A Randomized Clinical Trial
Open Access
- 1 December 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 3865-3875
Abstract
Background: Previous studies have demonstrated a significant relationship between vitamin D deficiency and the development of diabetic peripheral neuropathy (DPN). However, current studies are limited regarding the potential therapeutic benefits of vitamin D therapy in these patients. Objective: This study aimed to assess the effect of oral vitamin D supplementation in patients with diabetic peripheral neuropathy in addition to standard treatment. Methods: This study was a controlled, open-label, randomized clinical trial with an active comparator randomly allocated with a 1:1 ratio. The experimental group received an add-on oral vitamin D 5000 IU once daily and standard treatment (pregabalin, gabapentin, or amitriptyline) over eight weeks. The control group received standard treatment alone. The measured outcomes were the change in the score of the visual analog scale (VAS), numerical rating scale (NRS), and brief pain inventory (BPI). Vitamin D levels were also measured before and after the trial. Results: Data from 68 subjects with DPN was collected and analyzed. Most of them (60.3%) were female, aged 64.96 ± 8.3 years. After eight weeks of treatment, the experimental group showed a more significant reduction of mean VAS (− 3.34 ± 2.03 vs − 2.37 ± 2.2, p=0.044) and burning pain (1.76 ± 7.16 vs 6.18 ± 13.93, p=0.046) scores compared to controls. Mood also improves better in the experimental group (88.2% vs 70.6%, p=0.031). At the end of the study, vitamin D levels were also improved more significantly in the experimental group (40.02 ± 15.33 ng/mL vs 18.73 ± 6.88 ng/mL; p< 0.001) with greater changes from the baseline to week 8 (+24.14± 13.68 ng/mL vs +3.10± 4.20 ng/mL; p< 0.001) compared to control group. The intervention group showed a negative correlation between vitamin D level and VAS score (r = − 0.403, P = 0.018). There were no adverse events recorded in this study. Conclusion: The addition of oral vitamin D 5000 IU to standard treatment significantly improves pain, mood, and vitamin D levels more effectively than standard treatment alone in patients with diabetic neuropathy. Trial Registration: ClinicalTrials.gov.no NCT04689958.Keywords
This publication has 20 references indexed in Scilit:
- Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional surveyDiabetes, Metabolic Syndrome and Obesity, 2013
- Reversal of the Symptoms of Diabetic Neuropathy through Correction of Vitamin D Deficiency in a Type 1 Diabetic PatientCase Reports in Endocrinology, 2012
- Vitamin D Deficiency Promotes Skeletal Muscle Hypersensitivity and Sensory HyperinnervationJournal of Neuroscience, 2011
- Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001–2004 NHANESDiabetic Medicine, 2011
- Vitamin D Status in Relation to Glucose Metabolism and Type 2 Diabetes in SeptuagenariansDiabetes Care, 2011
- Vitamin D receptor and enzyme expression in dorsal root ganglia of adult female rats: Modulation by ovarian hormonesJournal of Chemical Neuroanatomy, 2011
- Vitamin D as an Analgesic for Patients With Type 2 Diabetes and Neuropathic PainArchives of internal medicine (1960), 2008
- Is Vitamin D Insufficiency Associated With Peripheral Neuropathy?The Endocrinologist, 2007
- The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2007
- A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathyJournal of Diabetes and its Complications, 2005